About Psychemedics (NASDAQ:PMD)
Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.
Industry, Sector and Symbol
Industry Medical laboratories
Trailing P/E Ratio22.79
Forward P/E RatioN/A
Sales & Book Value
Annual Sales$39.70 million
Price / Sales2.71
Cash Flow$1.5147 per share
Price / Cash12.94
Book Value$3.39 per share
Price / Book5.78
EPS (Most Recent Fiscal Year)N/A
Net Income$6.12 million
Return on Equity26.72%
Return on Assets18.48%
Psychemedics (NASDAQ:PMD) Frequently Asked Questions
What is Psychemedics' stock symbol?
Psychemedics trades on the NASDAQ under the ticker symbol "PMD."
How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?
Psychemedics announced a quarterly dividend on Tuesday, April 24th. Shareholders of record on Tuesday, May 8th will be paid a dividend of $0.18 per share on Friday, May 18th. This represents a $0.72 annualized dividend and a yield of 3.67%. The ex-dividend date is Monday, May 7th. This is a boost from Psychemedics's previous quarterly dividend of $0.15. View Psychemedics' Dividend History.
How were Psychemedics' earnings last quarter?
Psychemedics Corp. (NASDAQ:PMD) released its earnings results on Tuesday, April, 24th. The company reported $0.23 earnings per share (EPS) for the quarter. The company had revenue of $10.94 million for the quarter. Psychemedics had a return on equity of 26.72% and a net margin of 14.52%. View Psychemedics' Earnings History.
When is Psychemedics' next earnings date?
Who are some of Psychemedics' key competitors?
Who are Psychemedics' key executives?
Psychemedics' management team includes the folowing people:
- Mr. Raymond C. Kubacki Jr., Chairman, Chief Exec. Officer and Pres (Age 73)
- Mr. James V. Dyke, Corp. VP of Sales & Marketing (Age 53)
- Dr. Michael I. Schaffer Ph.D., VP of Laboratory Operations (Age 73)
- Dr. Werner A. Baumgartner Ph.D., Founder
- Ms. Annette Baumgartner, Founder
Has Psychemedics been receiving favorable news coverage?
Press coverage about PMD stock has been trending somewhat positive on Sunday, Accern reports. The research firm scores the sentiment of media coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Psychemedics earned a coverage optimism score of 0.13 on Accern's scale. They also gave headlines about the company an impact score of 45.77 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Psychemedics' major shareholders?
Psychemedics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Moors & Cabot Inc. (6.87%), Tieton Capital Management LLC (5.12%), Uniplan Investment Counsel Inc. (3.52%), Dimensional Fund Advisors LP (2.37%), Granite Investment Partners LLC (0.46%) and Seizert Capital Partners LLC (0.42%). Company insiders that own Psychemedics stock include Fred J Weinert, James V Dyke, Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr. View Institutional Ownership Trends for Psychemedics.
Which institutional investors are selling Psychemedics stock?
PMD stock was sold by a variety of institutional investors in the last quarter, including Granite Investment Partners LLC, Seizert Capital Partners LLC, Tieton Capital Management LLC, Uniplan Investment Counsel Inc. and JPMorgan Chase & Co.. Company insiders that have sold Psychemedics company stock in the last year include Michael I Schaffer and Neil Lerner. View Insider Buying and Selling for Psychemedics.
Which institutional investors are buying Psychemedics stock?
How do I buy shares of Psychemedics?
Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Psychemedics' stock price today?
One share of PMD stock can currently be purchased for approximately $19.60.
How big of a company is Psychemedics?
Psychemedics has a market capitalization of $107.65 million and generates $39.70 million in revenue each year. Psychemedics employs 231 workers across the globe.
How can I contact Psychemedics?
Psychemedics' mailing address is 289 GREAT ROAD, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.
MarketBeat Community Rating for Psychemedics (PMD)MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote "Outperform" if you believe PMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days.